These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22616020)

  • 1. Dengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responses.
    Chiang CY; Huang MH; Hsieh CH; Chen MY; Liu HH; Tsai JP; Li YS; Chang CY; Liu SJ; Chong P; Leng CH; Chen HW
    PLoS Negl Trop Dis; 2012; 6(5):e1645. PubMed ID: 22616020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice.
    Bernardo L; Pavón A; Hermida L; Gil L; Valdés I; Cabezas S; Linares R; Alvarez M; Silva R; Guillén G; Nagy E; Schlick P; Guzmán MG
    Vaccine; 2011 Jun; 29(25):4256-63. PubMed ID: 21447316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of robust immunity by the emulsification of recombinant lipidated dengue-1 envelope protein domain III.
    Chiang CY; Huang MH; Pan CH; Hsieh CH; Chen MY; Liu HH; Tsai JP; Liu SJ; Chong P; Leng CH; Chen HW
    Microbes Infect; 2013; 15(10-11):719-28. PubMed ID: 23774693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates.
    Chen HW; Liu SJ; Li YS; Liu HH; Tsai JP; Chiang CY; Chen MY; Hwang CS; Huang CC; Hu HM; Chung HH; Wu SH; Chong P; Leng CH; Pan CH
    Arch Virol; 2013 Jul; 158(7):1523-31. PubMed ID: 23456422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequence.
    Sun J; Li M; Wang Y; Hao P; Jin X
    Vaccine; 2017 Nov; 35(46):6308-6320. PubMed ID: 28987441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.
    Coller BA; Clements DE; Bett AJ; Sagar SL; Ter Meulen JH
    Vaccine; 2011 Sep; 29(42):7267-75. PubMed ID: 21777637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies.
    Batra G; Raut R; Dahiya S; Kamran N; Swaminathan S; Khanna N
    J Virol Methods; 2010 Jul; 167(1):10-6. PubMed ID: 20211204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice.
    García-Machorro J; López-González M; Barrios-Rojas O; Fernández-Pomares C; Sandoval-Montes C; Santos-Argumedo L; Villegas-Sepúlveda N; Gutiérrez-Castañeda B; Cedillo-Barrón L
    Hum Vaccin Immunother; 2013 Nov; 9(11):2326-35. PubMed ID: 23880886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.
    Clements DE; Coller BA; Lieberman MM; Ogata S; Wang G; Harada KE; Putnak JR; Ivy JM; McDonell M; Bignami GS; Peters ID; Leung J; Weeks-Levy C; Nakano ET; Humphreys T
    Vaccine; 2010 Mar; 28(15):2705-15. PubMed ID: 20097152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation in Mice of the Immunogenicity of a Tetravalent Subunit Vaccine Candidate Against Dengue Virus Using Mucosal and Parenteral Immunization Routes.
    Lazo Vázquez L; Gil González L; Marcos López E; Pérez Fuentes Y; Cervetto de Armas L; Brown Richards E; Valdés Prado I; Suzarte Portal E; Cobas Acosta K; Yaugel Novoa M; Romero Fernández Y; Guillén Nieto G; Hermida Cruz L
    Viral Immunol; 2017 Jun; 30(5):350-358. PubMed ID: 28418786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A vaccine formulation consisting of nucleocapsid-like particles from Dengue-2 and the fusion protein P64k-domain III from Dengue-1 induces a protective immune response against the homologous serotypes in mice.
    Lazo L; Gil L; López C; Valdés I; Blanco A; Pavón A; Romero Y; Guzmán MG; Guillén G; Hermida L
    Acta Trop; 2012 Nov; 124(2):107-12. PubMed ID: 22750482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of tetravalent and conserved synthetic peptides vaccines derived from Dengue virus Envelope domain I and II.
    Rocha RP; Livonesi MC; Fumagalli MJ; Rodrigues NF; da Costa LC; Dos Santos MC; de Oliveira Rocha ES; Kroon EG; Malaquias LC; Coelho LF
    Virus Res; 2014 Aug; 188():122-7. PubMed ID: 24768848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical and clinical development of a dengue recombinant subunit vaccine.
    Manoff SB; George SL; Bett AJ; Yelmene ML; Dhanasekaran G; Eggemeyer L; Sausser ML; Dubey SA; Casimiro DR; Clements DE; Martyak T; Pai V; Parks DE; Coller BA
    Vaccine; 2015 Dec; 33(50):7126-34. PubMed ID: 26458804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity.
    Leng CH; Liu SJ; Tsai JP; Li YS; Chen MY; Liu HH; Lien SP; Yueh A; Hsiao KN; Lai LW; Liu FC; Chong P; Chen HW
    Microbes Infect; 2009 Feb; 11(2):288-95. PubMed ID: 19114121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus.
    Lazo L; Izquierdo A; Suzarte E; Gil L; Valdés I; Marcos E; Álvarez M; Romero Y; Guzmán MG; Guillén G; Hermida Cruz L
    Microbiol Immunol; 2014 Apr; 58(4):219-26. PubMed ID: 24689365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant lipidated dengue-3 envelope protein domain III stimulates broad immune responses in mice.
    Chiang CY; Liu SJ; Hsieh CH; Chen MY; Tsai JP; Liu HH; Chen IH; Chong P; Leng CH; Chen HW
    Vaccine; 2016 Feb; 34(8):1054-61. PubMed ID: 26776472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.
    Lauretti F; Chattopadhyay A; de Oliveira França RF; Castro-Jorge L; Rose J; Fonseca BA
    Hum Vaccin Immunother; 2016 Sep; 12(9):2327-33. PubMed ID: 27185081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
    Arora U; Tyagi P; Swaminathan S; Khanna N
    Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant hemagglutinin proteins formulated in a novel PELC/CpG adjuvant for H7N9 subunit vaccine development.
    Chen TH; Liu YY; Jan JT; Huang MH; Spearman M; Butler M; Wu SC
    Antiviral Res; 2017 Oct; 146():213-220. PubMed ID: 28947234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys.
    Suzarte E; Gil L; Valdés I; Marcos E; Lazo L; Izquierdo A; García A; López L; Álvarez M; Pérez Y; Castro J; Romero Y; Guzmán MG; Guillén G; Hermida L
    Int Immunol; 2015 Aug; 27(8):367-79. PubMed ID: 25795768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.